Wall Street brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce sales of $3.50 million for the current quarter, Zacks reports. Five analysts have issued estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.10 million and the highest estimate coming in at $6.00 million. Xenon Pharmaceuticals posted sales of $3.33 million during the same quarter last year, which suggests a positive year over year growth rate of 5.1%. The business is expected to report its next earnings report on Monday, March 8th.
On average, analysts expect that Xenon Pharmaceuticals will report full-year sales of $30.50 million for the current financial year, with estimates ranging from $28.10 million to $33.00 million. For the next year, analysts expect that the company will post sales of $18.60 million, with estimates ranging from $11.30 million to $36.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Xenon Pharmaceuticals.
Separately, Zacks Investment Research lowered Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 22nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $21.50.
Xenon Pharmaceuticals stock traded up $0.19 during trading on Tuesday, reaching $16.17. The company had a trading volume of 185,496 shares, compared to its average volume of 136,557. Xenon Pharmaceuticals has a 12-month low of $7.00 and a 12-month high of $17.23. The stock’s 50 day moving average price is $15.40 and its two-hundred day moving average price is $12.59. The firm has a market capitalization of $566.06 million, a price-to-earnings ratio of -16.91 and a beta of 1.20.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy.
See Also: Options Trading – What is a Straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.